Dataset Information


Structural basis for the bypass of the major oxaliplatin-DNA adducts by human DNA polymerase ?.

ABSTRACT: Oxaliplatin, together with cisplatin, is among the most important drugs used in cancer chemotherapy. Oxaliplatin, which contains a bulky diaminocyclohexane (DACH) moiety, kills cancer cells mainly by producing (DACH)Pt-GpG intrastrand cross-links that impede transcription. The Pt-GpG tolerance by translesion DNA synthesis (TLS) polymerases contributes to the resistance of tumors to platinum-based chemotherapy. In particular, human DNA polymerase ? (Pol?) readily bypasses Pt-GpG adducts. While many structural studies have addressed how TLS polymerases interact with cisplatin-DNA adducts, a structure of DNA polymerase in complex with oxaliplatin-DNA adducts has not been reported, limiting our understanding of bypass of the bulky (DACH)Pt-GpG lesion by TLS polymerases. Herein, we report the first structure of DNA polymerase bound to oxaliplatinated DNA. We determined a crystal structure of Pol? incorporating dCTP opposite the 3'G of the (DACH)Pt-GpG, which provides insights into accurate, efficient bypass of the oxaliplatin-GpG adducts by TLS polymerases. In the catalytic site of Pol?, the 3'G of the (DACH)Pt-GpG formed three Watson-Crick hydrogen bonds with incoming dCTP and the primer terminus 3'-OH was optimally positioned for nucleotidyl transfer. To accommodate the bulky (DACH)Pt-GpG lesion, the Val59-Trp64 loop in the finger domain of Pol? shifted from the positions observed in the corresponding Pol?-cisplatin-GpG and undamaged structures, suggesting that the flexibility of the Val59-Trp64 loop allows the enzyme's bypass of the (DACH)Pt-GpG adducts. Overall, the Pol?-oxaliplatin-GpG structure provides a structural basis for TLS-mediated bypass of the major oxaliplatin-DNA adducts and insights into resistance to platinum-based chemotherapy in humans.

PROVIDER: S-EPMC6657808 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3362893 | BioStudies
| S-EPMC6052226 | BioStudies
| S-EPMC2475632 | BioStudies
| S-EPMC2996444 | BioStudies
| S-EPMC3572780 | BioStudies
| S-EPMC3103052 | BioStudies
| S-EPMC5643249 | BioStudies
| S-EPMC7746141 | BioStudies
| S-EPMC2449337 | BioStudies
| S-EPMC4139159 | BioStudies